MOONLAKE IMMUNOTHERAPEUTICS
MLTXNASDAQπ #2345 by market capEarnings Feb 24US Equity
$11.07β² $0.04 (+0.36%)
Market closed Β· at closeTrack MLTX
Get earnings, price moves & breaking news on Telegram
24hβ² 0.4%
7dβΌ 11.5%
14dβΌ 4.0%
30dβΌ 6.7%
ytdβΌ 15.9%
1yβΌ 12.6%
π¦Market Cap
$942M
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
0.0%
Thin
π΅FCF Margin
0.0%
Thin
βοΈP/S Ratio
0.0x
Cheap
Otter Score
48
Weak
Trading Snapshot
- Day Range
- $10.72 β $11.31
- 52-Week Range
- $9.46 β $23.29
- Volume (shares)
- 1,723,799
- Avg Volume (shares)
- β
- Shares Outstanding
- 85.1M
- Next Earnings
- 2027-02-24
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -3.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.20
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.2%
MOONLAKE IMMUNOTHERAPEUTICS
MLTXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$245Mβ² +71.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$196Mβ² +67.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
64.5Mβ² +2.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$259Mβ² +$81M YoY
About MOONLAKE IMMUNOTHERAPEUTICS
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Weak
48/100
Analyst data unavailable.
Latest News & Updates
News unavailable.